TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22923753
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 400 mg at weeks 0, 2, and 4, followed by 200 mg every 2 weeks
Study: 9834045
Drug: N-0861 (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-0861 (specific doses administered via bolus and maintenance infusion)
Study: 2768542
Drug: Haloperidol (4-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (4-16 mg/day)
Study: 2768542
Drug: Amitriptyline (100-175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (100-175 mg/day)
Study: 22049162
Drug: Lysine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine intake ranging from 15 to 240 mg · kg(‐1) · d(‐1)
Study: 11707785
Drug: 3-injection technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-injection technique (group 3N)
Study: 11707785
Drug: 2-injection technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-injection technique (group 2N)
Study: 27847634
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (2q4)
Study: 30946887
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IAI) 2 mg every 8 weeks after 5 monthly doses (2q8)
Study: 24899557
Drug: One‐to‐one oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: One‐to‐one oral instruction strategy combined with an information sheet
Study: 11872893
Drug: Immunosuppressive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive and anticoagulant therapy
Study: 10455841
Drug: Intravenous tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tramadol 1.5 mg.kg-1
Study: 2403867
Drug: Intravenous aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous aspirin (60 mg the first day and 20 mg on successive days)
Study: 2403867
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of isosorbide dinitrate and oral diltiazem
Study: 2403867
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of aspirin and vasodilators
Study: 2403867
Drug: Full therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full therapy including heparin and beta-blockers
Study: 26714411
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Acarbose and Metformin)
Study: 10598693
Drug: Dorzolamide-timolol combination
Normalized name: dorzolamide / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide-timolol combination (COSOPT) twice daily
Study: 30354794
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading 1 μg/kg over 20 min followed by infusion at 0.5 μg/kg/h)
Study: 14975380
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (50 microg) plus fentanyl (50 microg)
Study: 22123713
Drug: Dose-dense TC
Normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense TC with severe anemia (hemoglobin <8.0 g/dL)
Study: 22123713
Drug: Dose-dense TC
Normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense TC without severe anemia (hemoglobin >8.0 g/dL)
Study: 10799160
Drug: Antibiotics (rifampin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (rifampin, doxycycline, erythromycin, metronidazole, clindamycin, amoxicillin, ciprofloxacin) for 18 weeks
Study: 9275368
Drug: Artesunate at
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate at a dose of 6 mg/kg once a week for 8 weeks
Study: 6853785
Drug: Diflorasone diacetate
Normalized name: Diflorasone Diacetate
DrugBank: Diflorasone (DB00223)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diflorasone diacetate (DD) ointment
Study: 30814413
Drug: Okara (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Okara (60 g/day for 2 weeks)
Study: 25483421
Drug: Chlorhexidine (CHD)
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine (CHD) solution, wiped till day seven of life
Study: 25483421
Drug: Chlorhexidine (CHD)
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine (CHD) solution
Study: 24819981
Drug: Total urinary
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total urinary resveratrol metabolites (mean concentration 7.08 nmol/g of creatinine)
Study: 16813032
Drug: Intranasal aqueous
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal aqueous triamcinolone spray
Study: 6381065
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and oral mexiletine
Study: 26309191
Drug: MAGE-A3 immunotherapeutic
Normalized name: Kitasamycin A3
DrugBank: Josamycin (DB01321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAGE-A3 immunotherapeutic (300 μg recombinant MAGE-A3 formulated with AS15) administered concurrently with standard cisplatin/vinorelbine chemotherapy (cohort 1)
Study: 26309191
Drug: MAGE-A3 immunotherapeutic
Normalized name: Kitasamycin A3
DrugBank: Josamycin (DB01321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAGE-A3 immunotherapeutic administered after standard chemotherapy (cohort 2)
Study: 26309191
Drug: MAGE-A3 immunotherapeutic
Normalized name: Kitasamycin A3
DrugBank: Josamycin (DB01321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAGE-A3 immunotherapeutic administered without standard chemotherapy (cohort 3)
Study: 26309191
Drug: MAGE-A3 immunotherapeutic
Normalized name: Kitasamycin A3
DrugBank: Josamycin (DB01321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAGE-A3 immunotherapeutic administered after standard radiotherapy and/or chemotherapy (cohort 4)
Study: 27193080
Drug: Intravenous tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tramadol (2 mg/kg)
Study: 19401664
Drug: Peritonsillar infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritonsillar infiltration of tramadol (2 mg/kg in 2 ml normal saline)
Study: 15523663
Drug: Periconceptional multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periconceptional multivitamin supplementation containing folic acid (0.8 mg)
Study: 11736724
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg daily for 8 days)
Study: 11736724
Drug: Rabeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (20 mg daily for 8 days)
Study: 9369816
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution with 5% glucose (n = 48)
Study: 9369816
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution without glucose (n = 43)
Study: 26590384
Drug: Mean on-treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mean on-treatment SBP 130-139 mmHg or DBP 80-89 mmHg
Study: 18568228
Drug: Mechanical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical treatment - 0.4 mm beads
Study: 18568228
Drug: Mechanical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical treatment - 0.6 mm beads
Study: 18568228
Drug: Chemical/mechanical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical/mechanical treatment - 0.4 mm beads
Study: 18568228
Drug: Chemical/mechanical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical/mechanical treatment - 0.6 mm beads
Study: 16238901
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg intravenous test dose of paclitaxel or docetaxel
Study: 16238901
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose of paclitaxel or docetaxel without a test dose
Study: 7579056
Drug: Cyclosporine monotherapy
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine monotherapy (CsA)
Study: 2284832
Drug: Hydrocolloid dressing
Normalized name: hydrocolloid dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocolloid dressing containing anthralin (0.02 to 0.20 mg/cm2)
Study: 2284832
Drug: Short-contact therapy
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-contact therapy with anthralin alone
Study: 25634195
Drug: 3-L split-dose
Normalized name: 3-(L-MENTHOXY)-2-METHYLPROPANE-1,2-DIOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-L split-dose PEG
Study: 15651179
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amphotericin B and fluconazole
Study: 15651179
Drug: Echinocandins in
Normalized name: Echinocandin B, 1-((4R,5R)-4-hydroxy-N2-((4''-(pentyloxy)(1,1':4',1''-terphenyl)-4-yl)carbonyl)-5-(2-(trimethylammonio)ethoxy)-l-ornithine)-4-((4S)-4-hydroxy-4-(4-hydroxyphenyl)-l-allothreonine)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinocandins in combination with triazoles
Study: 15651179
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of echinocandin to monotherapy for aspergillosis
Study: 9756589
Drug: No acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: No acupuncture treatment (control group)
Study: 31828291
Drug: High-dose trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose trivalent vaccine
Study: 31828291
Drug: Standard-dose quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose quadrivalent vaccine
Study: 17976882
Drug: Escitalopram 10-20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10-20 mg/day for 12 weeks
Study: 12851511
Drug: Oral hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hormone replacement therapy (2 mg daily of 17beta-estradiol plus 10 mg dydrogesterone daily for 14 days of each 28-day cycle)
Study: 10541423
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 180 mg QD
Study: 31201653
Drug: Brief cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive behavioral therapy (bCBT)
Study: 19320663
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin three times daily before meals
Study: 19320663
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine administered in the morning before breakfast
Study: 11332784
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment
Study: 11239727
Drug: 6-session cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-session cognitive-behavioral therapy (CBT) program
Study: 9402774
Drug: Subcutaneous octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous octreotide 50 micrograms twice daily for 6 months with programmed injection sclerotherapy
Study: 9402774
Drug: Programmed injection
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed injection sclerotherapy alone
Study: 30522512
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health intervention including oral health education sessions and daily oral self-care under caregiver supervision.
Study: 22820824
Drug: Deep heating
Normalized name: Mentholatum Deep Heating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep heating therapy (DHT) via local microwave diathermy (three 30‐min sessions a week for four weeks)
Study: 22820824
Drug: Superficial heating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superficial heating therapy (SHT) via application of hot packs (three 30‐min sessions a week for four weeks)
Study: 23185342
Drug: Expectation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectation of taking an immunosuppressant
Study: 15985509
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at the Quchi (LI11) acupoint thrice weekly for 1 month
Study: 15985509
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at a non‐acupoint 2 cm lateral to Quchi (LI11) thrice weekly for 1 month
Study: 9154882
Drug: Isoniazid (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid (oral administration)
Study: 21690572
Drug: Vinorelbine or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine or paclitaxel-containing chemotherapy
Study: 11090595
Drug: 6.0 g
Normalized name: MENTHOL 6.0 g in 100 g TOPICAL GEL [RockSauce ICE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.0 g fish oil daily for 6 weeks
Study: 3888046
Drug: Synthetic androgen
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic androgen fluoxymesterone for 3 days before and on the day of chemotherapy
Study: 3888046
Drug: Aminoglutethimide and
Normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminoglutethimide and hydrocortisone plus cyclic chemotherapy
Study: 14732657
Drug: 40% urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% urea cream applied to half of the treatment area
Study: 14732657
Drug: topical 3%
Normalized name: sulfur topical 3% topical soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical 3% lidocaine hydrochloride applied 45 minutes before treatment
Study: 14732657
Drug: vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle cream applied to half of the treatment area
Study: 14732657
Drug: vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle cream applied 45 minutes before treatment
Study: 9563529
Drug: Delayed laparoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed laparoscopic cholecystectomy after initial medical treatment
Study: 25802354
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (TCSs)
Study: 23415344
Drug: Short-term educational
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term educational intervention (24 units) in human biology based on Evidence-based Medicine (EbM) and Good Scientific Practice (GSP)
Study: 16107866
Drug: Citalopram 20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20 mg oral daily
Study: 14871283
Drug: Balsalazide (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balsalazide (750 mg capsules, two capsules twice daily, increased by 750 mg increments to a maximum of 6 g for up to 7 days)
Study: 10096243
Drug: FAC/FEC treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAC/FEC treatment
Study: 30829429
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1 µg kg‐1 h‐1
Study: 12521277
Drug: Calcium lactate
Normalized name: Calcium Lactate
DrugBank: Calcium lactate (DB13231)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium lactate (3 g daily)
Study: 9806564
Drug: Fixed-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose regimen
Study: 9806564
Drug: Low-dose step-up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose step-up regimen
Study: 25127878
Drug: Qigong intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Qigong intervention (2-hour group training twice a week for 6 weeks, 1-hour follow-up group session once a week for 4 months, 30-minute self-practice daily for 5.5 months)
Study: 24321402
Drug: Pre-conception treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-conception treatment including dental scaling and root planning, supragingival prophylaxis, and oral hygiene education
Study: 24321402
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving supragingival prophylaxis and oral hygiene education
Study: 3886274
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (treatment)
Study: 10817793
Drug: Cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based chemotherapy (3 courses)
Study: 6149824
Drug: Treadmill exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treadmill exercise test on placebo and beta-blocker in patients with CAD
Study: 21911720
Drug: Venlafaxine 75
Normalized name: venlafaxine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 75 mg
Study: 23621628
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with intracameral and subconjunctival injections of bevacizumab (1.25 mg/0.05 mL) and subconjunctival injections of 5‐FU (5.0 mg/0.5 mL)
Study: 23621628
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with 5‐FU (5.0 mg/0.5 mL)
Study: 9038037
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER 5 mg (F5)
Study: 9038037
Drug: Nifedipine Retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine Retard 10 mg (N20)
Study: 9038037
Drug: Nifedipine Retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine Retard 20 mg (N40)
Study: 7557846
Drug: no therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: no therapy (control)
Study: 8692739
Drug: Intravenous montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous montelukast sodium (3, 9, and 18 mg)
Study: 8692739
Drug: Oral montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral montelukast sodium (10 mg) in females
Study: 30638739
Drug: Four-oil lipid
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-oil lipid emulsion (30% soybean oil, 30% medium-chain triglycerides, 25% olive oil, 15% fish oil) administered continuously for 5 days, FO dose of 0.09-0.22 g/kg body weight.
Study: 30638739
Drug: 100% soybean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% soybean oil lipid emulsion administered continuously for 5 days.
Study: 30680401
Drug: SPR periodontal
Normalized name: betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SPR periodontal basic treatment
Study: 20617588
Drug: Human serum
Normalized name: Human serum albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human serum immunoglobulin treatment
Study: 11833075
Drug: High-dose iodized
Normalized name: calcium iodized
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose iodized oil TACE (more than 20 mL Lipiodol)
Study: 11833075
Drug: Routine dose
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine dose iodized oil TACE (5-15 mL Lipiodol)
Study: 10362425
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide at doses of < or =5 ppm
Study: 10362425
Drug: Prolonged inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged inhaled nitric oxide at doses of < or =20 ppm
Study: 7722713
Drug: Nutritional supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplementation (specifics on dosage and duration not available)
Study: 2040466
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg) three times a day for three days
Study: 6389470
Drug: Intravenous acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acyclovir (5 mg/kg three times daily for five days)
Study: 6389470
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (400 mg five times daily for five days)
Study: 8708685
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injections
Study: 27281233
Drug: Vacuum sealing
Normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum sealing drainage (VSD) and antibiotic‐loaded bone cement
Study: 24932979
Drug: Control: Lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: Lidocaine with epinephrine (1.84 mL solution: 36.8 mg lidocaine with 18.4 μg epinephrine)
Study: 22227226
Drug: robenacoxib (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: robenacoxib (2 mg/kg)
Study: 22227226
Drug: meloxicam (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: meloxicam (0.3 mg/kg)
Study: 7799476
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 g of calcium carbonate and 4 mg of sodium chloride)
Study: 24848384
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine infusion (6 μg/kg/minute)
Study: 23731195
Drug: Active formulation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active formulation containing licochalcone A, l-carnitine and 1,2-decanediol applied twice daily for 8 weeks